These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 16820380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis.
    Burgos-Vargas R, Rojas-Serrano J.
    J Rheumatol; 2005 Sep; 32(9):1637-40. PubMed ID: 16142852
    [No Abstract] [Full Text] [Related]

  • 5. Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers.
    Saeed A, Khan M, Elmamoun M, Brady M, Morrissey S, Fraser AD.
    Rheumatol Int; 2012 May; 32(5):1305-9. PubMed ID: 21286722
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
    Kobelt G.
    Rheumatology (Oxford); 2008 Oct; 47(10):1589-90; author reply 1590; discussion 1590-1. PubMed ID: 18710898
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Canadian recommendations for the management of spondyloarthritis address many different levels of patient care.
    Braun J.
    Nat Clin Pract Rheumatol; 2008 May; 4(5):234-5. PubMed ID: 18334982
    [No Abstract] [Full Text] [Related]

  • 11. Recognition and treatment of juvenile-onset spondyloarthritis.
    Gensler L, Davis JC.
    Curr Opin Rheumatol; 2006 Sep; 18(5):507-11. PubMed ID: 16896291
    [Abstract] [Full Text] [Related]

  • 12. TNF inhibitors for ankylosing spondylitis in the real world.
    McVeigh CM, Bell AL, Cairns AP.
    Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
    [No Abstract] [Full Text] [Related]

  • 13. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
    Temel M, Atagündüz P, Direskeneli H.
    Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
    Escalas C, Trijau S, Dougados M.
    Rheumatology (Oxford); 2010 Jul; 49(7):1317-25. PubMed ID: 20360041
    [Abstract] [Full Text] [Related]

  • 17. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR, Tavares V, Da Silva JC.
    Acta Med Port; 2006 Jul; 19(2):141-50. PubMed ID: 17187716
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report.
    Cay HF, Gungor HA, Sezer I, Kacar C, Balci N.
    J Clin Pharm Ther; 2006 Dec; 31(6):645-8. PubMed ID: 17176371
    [Abstract] [Full Text] [Related]

  • 20. Switching anti-TNF therapy in ankylosing spondylitis.
    Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C.
    Rheumatology (Oxford); 2008 Nov; 47(11):1726-7. PubMed ID: 18782856
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.